Abstract:Background: SPARC (secreted protein acidic and rich in cystein) is a secreted glycoprotein that interacts with extracellular matrix protein and acts as a regulator of critical cellular functions such as proliferation and cell migration. An increasing number of studies have shown altered expression of SPARC in several malignancies. However, the role of this potential biomarker in breast cancer development and progression is controversial. Triple-negative breast cancer (TNBC) is known for its poor prognosis and high recurrence probability. There is a need for prognostic biomarkers to guide treatment decisions for this subtype. Objective: To explore the association between SPARC and the prognosis of triple-negative breast cancer. Methods: In this study, a total of 211 samples of triple-negative breast lesions from 2004 to 2008 were collected in Cancer Hospital, Chinese Academy of Medical Sciences. SPARC expression was evaluated by immunohistochemistry using an immunoreactive score (IRS) from patients with up to 10 years clinical follow-up data. The current study set out to examine both the expression of SPARC in primary tumor tissue and to demonstrate if a link existed between the levels of SPARC and the clinical outcome. Cox proportional hazards model was used to estimate HRs and 95%CI, stratified on tumor grade, TNM stage, lymph node status and vascular invasion. Results: High SPARC expression (IRS≥3) was observed in 52.1% of all primary tumors. Patients expressing low levels of SPARC had better disease-free survival (DFS) (HR=0.632, 95%CI:0.405-0.987, P = 0.044) as well as overall survival(OS)(HR=0.576, 95%CI:0.351-0.946, P = 0.029) compared to those with high SPARC expression levels.Furthermore, the presence of high SPARC expression was an independent prognostic factor for both DFS (HR=1.67, 95%CI:1.04-2.69, P=0.034) and OS(HR=1.77, 95%CI:1.04-3.01, P=0.037) of triple-negative breast cancer patients, stratified on tumor grade, TNM stage, lymph node metastasis and vascular invasion, with adjustment for age, hormonal status, tumor size, adjuvant radiotherapy and adjuvant chemotherapy. Conclusion: Our results suggest that the presence of higher SPARC expression could be an indicator of high aggressiveness and may be a strong prognostic factor for triple-negative breast cancer. Citation Format: Zhu A, Yuan P, Du F, Ding X, Xu B. Impact of high SPARC expression of a primary tumor as a strong risk factor for disease recurrence and overall survival in patients with triple-negative breast cancer. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P3-07-60.

Sparc Expression in Primary Tumor and Metastatic Lymph Node of Resected Pancreatic Cancer Patients and Its Impact on Prognosis.

The Relationship Between SPARC Expression in Primary Tumor and Metastatic Lymph Node of Resected Pancreatic Cancer Patients and Patients' Survival.

Systematic Review/meta-analysis Prognostic Role of Sparc Expression in Gastric Cancer: a Meta-analysis

Prognostic role of SPARC expression in gastric cancer: a meta-analysis.

Identification of Spindle and Kinetochore-Associated Family Genes As Therapeutic Targets and Prognostic Biomarkers in Pancreas Ductal Adenocarcinoma Microenvironment

Correlation Between Secreted Protein Acidic and Rich in Cysteine Protein Expression and the Prognosis of Postoperative Patients Exhibiting Esophageal Squamous Cell Carcinoma

Abstract P3-07-60: Impact of High SPARC Expression of a Primary Tumor As a Strong Risk Factor for Disease Recurrence and Overall Survival in Patients with Triple-Negative Breast Cancer

Prognostic Role of Secreted Protein Acidic and Rich in Cysteine in Patients with Solid Tumors

SPARC Expression in Primary Tumor and Metastatic Lymph Node of Resected Pancreatic Cancer Patients: A Single Center Experience

SPARC is a Novel Prognostic Biomarker for Ovarian Cancer and Associated with Immune Signatures and Drug Response

SPARC Overexpression Promotes Liver Cancer Cell Proliferation and Tumor Growth

SPARC expression is negatively correlated with clinicopathological factors of gastric cancer and inhibits malignancy of gastric cancer cells.

Low Levels of SPARC are Associated with Tumor Progression and Poor Prognosis in Human Endometrial Carcinoma

The identification of liver metastasis- and prognosis-associated genes in pancreatic ductal adenocarcinoma

SPARC Promotes the Proliferation and Metastasis of Oral Squamous Cell Carcinoma by PI3K/AKT/PDGFB/PDGFRβ Axis

Increased Sphingosine Kinase 1 Expression is Associated with Poor Prognosis in Human Solid Tumors: A Meta-Analysis

Aberrant methylation of the SPARC gene promoter and its clinical implication in gastric cancer

Immunological role and prognostic value of SPARCL1 in pan-cancer analysis

Clinical Correlates and Prognostic Value of Different Metastatic Sites in Gastric and Colorectal Signet Ring Cell Carcinoma

Hypermethylation of the SPARC Promoter and Its Prognostic Value for Prostate Cancer.

SPARCL1, Shp2, MSH2, E-cadherin, P53, ADCY-2 and MAPK Are Prognosis-Related in Colorectal Cancer